Marker Therapeutics (MRKR) Falls 20.6% After Positive Clinical Study
Called the Apollo study, Marker Therapeutics, Inc. (NASDAQ:MRKR) said that its multi-antigen recognizing T cell therapy registered an objective response rate of 66 percent in patients with Non-Hodgkin...